• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6493.TWO
Share

Ttbio Corp. Stocks

NT$ 43.8Last Updated 24.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

NT$ 35.61M

NT$ 43.8
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ttbio Corp. specializes in the development, distribution, and after-sales support of medical devices under its proprietary TTBIO brand, serving both the Taiwanese domestic market and a global clientele. Its product offerings include a range of high-speed and low-speed dental handpieces, alongside essential dental spare components, service rotors, maintenance systems, and advanced electric handpiece solutions. Beyond its core medical device portfolio, Ttbio is also a key supplier of high-precision machined parts and custom components. These are engineered to cater to diverse sectors such as automotive, aerospace, security, and computing hardware, in addition to providing parts for general industrial maintenance and specialized custom projects. Established in 2012, Ttbio Corp. maintains its headquarters in Taichung, Taiwan.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 6493.TWO is 169 and suggests 324% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.07.2026 23:10

Freedom recommended buying Alphabet stock after the pullback. What could hinder its growth?

24.07.2026 22:45

Key Developments in the Kazakh Market: The Stakes of the Oil War and Signals from the National Bank

24.07.2026 22:34

"The Divorce of the Century": SK CEO to Pay Ex-Wife $643 Million but Retain Control of SK Hynix

24.07.2026 21:54

A Wake-Up Call That Could Transform the AI Market: What to Look for in Hyperscalers’ Reports

24.07.2026 21:23

Brent crude fell 5%. Reuters reported on an attempt to resume negotiations between the U.S. and Iran

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026